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Abstract
Introduction: Hospital-acquired pneumonia (HaP) of-
ten  occurring  as  ventilator-associated  pneumonia
(vaP) is the most frequent hospital infection in inten-
sive  care  units  (Icu).  Early  adequate  antimicrobial
therapy  is  an  essential  determinant  of  clinical  out-
come. organisations like the German PEG or ats/
Idsa provide guidelines for the initial calculated treat-
ment  in  the  absence  of  pathogen  identification.  We
conducted  a  retrospective  chart  review  for  patients
with HaP/vaP and assessed whether the initial intra-
venous antibiotic therapy (IIat) was adequate accord-
ing to the PEG guidelines
Materials and Methods: We collected data from 5 ter-
tiary care hospitals. Electronic data filtering identified
895 patients with potential HaP/vaP. after chart re-
view we finally identified 221 patients meeting the def-
inition of HaP/vaP. Primary study endpoints were
clinical improvement, survival and length of stay. sec-
ondary  endpoints  included  duration  of  mechanical
ventilation, total costs, costs incurred on the intensive
care unit (Icu), costs incurred on general wards and
drug costs.
Results: We found that 107 patients received adequate
initial  intravenous  antibiotic  therapy  (IIat)  vs.  114
with  inadequate  IIat  according  to  the  PEG  guide-
lines. baseline characteristics of both groups revealed
no  significant  differences  and  good  comparability.
clinical improvement was 64% over all patients and
82%  (85/104)  in  the  subpopulation  with  adequate
IIat  while  only  47%  (48/103)  inadequately  treated
patients improved (p< 0.001). the odds ratio of thera-
peutic  success  with  Ga  versus  nGa  treatment  was
5.821 (p<0.001, [95% cI: 2.712-12.497]). survival was
80% for the total population (n = 221), 86% in the ad-
equately treated (92/107) and 74% in the inadequately
treated subpopulation (84/114) (p = 0.021). the odds
ratio  of  mortality  for  Ga  vs.  nGa  treatment  was
0.565  (p=0.117,  [95%  cI:  0.276-1.155]).  adequately
treated patients had a significantly shorter length of
stay (los) (23.9 vs. 28.3 days; p = 0.022), require sig-
nificantly less hours of mechanical ventilation (175 vs.
274;  p  =  0.001),  incurred  lower  total  costs  (EuR
28,033 vs. EuR 36,139, p = 0.006) and lower Icu-re-
lated costs (EuR 13,308 vs. EuR 18,666, p = 0.003).
drug costs for the hospital stay were also lower (EuR
4,069 vs. EuR 4,833) yet not significant. the most fre-
quent types of inadequate therapy were monotherapy
instead of combination therapy, wrong type of peni-
cillin and wrong type of cephalosporin.
Discussion:  these findings are consistent with those
from other studies analyzing the impact of guideline
adherence on survival rates, clinical success, los and
costs.  However,  inadequately  treated  patients  had  a
higher complicated pathogen risk score (cPRs) com-
pared  to  those  who  received  adequate  therapy.  this
shows that therapy based on local experiences may be
sufficient for patients with low cPRs but inadequate
for those with high cPRs. linear regression models
showed that single items of the cPRs like extrapul-
monary organ failure or late onset had no significant
influence on the results.
Conclusion: Guideline-adherent initial intravenous an-
tibiotic therapy is clinically superior, saves lives and is
less  expensive  than  non  guideline  adherent  therapy.
using a cPRs score can be a useful tool to determine
the right choice of initial intravenous antibiotic thera-
py. the net effect on the German healthcare system
per  year  is  estimated  at  up  to  2,042  lives  and  EuR
125,819,000 saved if guideline-adherent initial therapy
for HaP/vaP were established in all German Icus.
List of  abbreviations: 
alos = average length of stay in a given dRG, basis for 
determining  whether  a  patient  causes  more  costs  than  re  -
imbursement; 
los = length of stay in hospital; 
HaP = Hospital acquired pneumonia; 
vaP = ventilator-associated pneumonia; 
caP = community acquired pneumonia; 
dRG = diagnoses related groups, systems to classify patients
based on their resource consumptions; 
cW = cost-weight of a given dRG, directly related to clinical
and economical “severity” (resource consumption); 
cPRs = complicated pathogen risk score; 
Icd = International classification of diseases; 
Icd-10 = Icd, Revision 10; 
PdX = Primary diagnosis (in Icd-10); 
sdX = secondary diagnosis (in Icd-10); 
HMv = Hours of mechanical ventilation; 
Icu = Intensive care unit; 
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4. Wilke_Umbruchvorlage  12.07.11  11:32  Seite 315Icu days = treatment days on an intensive care unit; MRsa
= Methicillin-resistant staphylococcus aureus; 
cI = clinical improvement; 
PEG  =  Paul-Ehrlich  Gesellschaft,  providing  guidelines  on
antibiotic therapy; 
ats = american thoracic society; 
blI = beta-lactamase inhibitor; 
lRtI = lower respiratory tract infection; 
IIat = Initial intravenous antibiotic therapy; 
Ga = IIat according to guideline = guideline adherent; 
nGa = IIat not according to guideline = non-guideline ad-
herent
IntRoductIon
as  a  growing  problem  in  patient  care,  hospital-ac-
quired infections require particular attention in inten-
sive care patients since they are significantly associated
with worse outcomes [1] and higher costs [2-4]. Pneu-
monia (lRtI) is the most prevalent infection among
Icu-patients [5, 6, 7]. the incidence of vaP ranges
between 9.3 and 13.6 cases per 1,000 ventilation days.
Early adequate antimicrobial therapy is an essential de-
terminant of clinical outcome. choosing the appropri-
ate agent, however, remains challenging since in most
cases no data on the identity and susceptibility of the
pathogen is available at the time of treatment initia-
tion [8-12].
several  guidelines  on  the  initial  therapy  of  HaP
and vaP were developed in the last years. Recently,
updated versions of the recommendations issued by
the ats/Idsa (usa) and PEG (Germany) were pub-
lished [13-15]. these guidelines acknowledge the risk
of difficult-to-treat pathogens as causative agents of
nosocomial pneumonia. the recommended regimens
include  monotherapy  with  acylaminopenicillines  +
beta-lactamase  inhibitors,  3rd  generation  cephalo  -
sporins, quinolones, carbapenemes and various combi-
nation regimens. 
so far only a few published studies investigated the
impact of clinician adherence to therapeutic guidelines
on  clinical  outcomes  or  at  least  the  usefulness  of
guidelines in clinical care [16-18]. We investigated the
effects of guideline adherence on clinical and econom-
ical outcomes of patients with HaP/vaP in the Icu. 
MatERIals and MEtHods
German hospitals collect and submit vast amounts of
administrative, clinical data. a subset of approximately
250  hospitals  additionally  provides  cost  data.  these
data are primarily used for the annual evaluation and
cost calculation within the German dRG-system (G-
dRG). these datasets are frequently used in clinical-
economical  analyses  as  they  include  all  primary  and
secondary diagnoses (Icd-10 encoded) [19-24]. 
We investigated HaP/vaP outcomes and therefore
focussed on Icd codes representing pneumonia as a
secondary  diagnosis.  In  our  study  we  collected  the
above-specified  data  from  5  hospitals  (2  university
hospitals and 3 major urban tertiary hospitals). these
hospitals  were  selected  because  we  assumed  that
guidelines adherence was highest in tertiary care and
university  hospitals.  Moreover  the  selected  hospitals
participate  in  the  German  dRG  annual  evaluation
program. the German Institute for the Hospitals Re-
muneration system (InEK) that performs these evalu-
ations uses high quality standards regarding cost data.
together with clinical advisors we selected the pa-
tient population of interest. as HaP/vaP are specifi-
cally relevant on Icu [5, 9, 25], we used the recom-
mendations of the PEG guidelines for adults to deter-
mine  whether  a  given  initial  intravenous  antibiotic
therapy (IIat) was adherent to guidelines. thus we
only included patients who where at least 18 years old
at the time of treatment initiation.
Identifying patients for clinical economic analyses
from  dRG-related  data  has  certain  limitations  and
therefore  needs  special  attention.  the  diagnoses  are
encoded in Icd-10 GM (German modification). a pa-
tient has a primary diagnosis (PdX) which is the retro-
spectively  identified  cause  for  hospitalization.  Each
dataset also contains a number of secondary diagnoses
(sdX).  a  sdX  must  be  documented  if  the  disease
caused  significant  resource  consumption  during  the
hospital stay. some sdXs, the so-called complications
and comorbidities (cc), are cost-relevant within the
dRG system. In the German dRG dataset an sdX
has no date and no flag whether it is already present
on admission (Poa) or not. thus the mere existence
of a pneumonia code among the sdXs does not un-
equivocally  indicate  a  HaP/vaP.  However,  since
2009/10 the Icd-10 GM includes the code u69.00 as
an indicator sdX for HaP/vaP, making HaP/vaP
identification much easier. 
In our dataset we excluded all patients with pneu-
monia  or  exacerbated  coPd  as  PdX.  all  patients
having a pneumonia code as sdX and no such code as
PdX were included.
the PEG guidelines (2004/2005 version) for IIat
of HaP are similar to the ats or Idsa guidelines in
terms of the therapeutic options. We chose the PEG
recommendations  since  they  provide  a  convenient
scoring  system  that  defines  three  different  patient
groups based on the risk of the involvement of com-
plicated pathogens. [26-31].
table 1a provides an overview to the cPRs system
in  the  PEG-recommendations.  table  1b  shows  the
therapy recommendations depending on the calculated
score.
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Table  1a.  Risk  factors  associated  with  the  involvement  of
complicated bacterial pathogens in HaP/vaP.
Risk factor Score 
age > 65 yrs 1
structural lung disease (e.g. coPd) 2
Previous antibiotic treatment  2
late onset (5 or more days after admission) 3
Invasive or non-invasive mechanical ventilation on  3
onset date
Extrapulmonary organ failure  4
the total complicated pathogen risk score (cPRs) is calculat-
ed by adding up all individual scores for risk factors identified
in a given patient.
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with probable HaP/vaP. We then performed the fol-
lowing analyses via medical chart review (if available):
• check Icd coding and medical documentation to
verify if HaP/vaP was present and patient can be
included.
• checking other inclusion/exclusion criteria like the
Icu-days (max 20 days)
• determine the HaP/vaP date of onset using radi-
ology results, laboratory findings and clinical docu-
mentation [25]
• calculate the cPRs according to PEG recommen-
dations [15] 
• document IIat starting with the date of onset.
• compare the actual IIat to the PEG recommenda-
tions 
• determine whether the treatment was adequate or
non-adequate according to the PEG guidelines. the
criterion of IIat adequacy was used to divide the
cohort in two subpopulations. 
• check  ‘clinical  improvement’  as  documented  by
laboratory  results,  radiology  or  clinical/nursing
documentation, and respiratory parameters in me-
chanically ventilated patients. clinical improvement
was defined as improvement of respiratory parame-
ters, decreasing cRP, decreasing Wbc and/or radi-
ological signs of improvement. the patient was cat-
egorized  as  ‘improved’  only  if  improvement  oc-
curred  within  4  days  of  treatment  initiation.  Pa-
tients  with  unclear  improvement  status  data  were
categorized as indeterminate. 
• the chart review was performed by two clinical in-
fectious disease specialists. In addition, the charts
were reviewed by Icd coding experts to determine
whether coding was correct. 
for the patients included in the final analysis set, we
gathered the data listed in table 2 for further analysis.
table 3 shows the primary and secondary endpoints of
the statistical analysis.
REsults
In total, we received 211,084 datasets from the 5 hos-
pitals for the year 2007. through the initial data filter
we identified 895 patients with probable HaP/vaP.
647 patients were excluded during chart reviews. for
223 patients the medical record was missing (could not
be retrieved) or not complete (e.g. laboratory or mi-
crobiology data). 166 patients turned out to be cases
with caP. this is due to the fact that pneumonia and
another relevant condition were already present on ad-
mission but the other diagnosis was chosen as primary
diagnosis for dRG purposes. In most cases this was
acute left-heart failure combined with pneumonia. In
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Table 1b. PEG therapeutic recommendations for HaP/vaP depending on the complicated pathogen risk score (cPRs).
Group I (cPRs = 1 or 2) aminopenicillin/blI or cephalosporin 2/3a or quinolone 3/4 or carbapenem 2
Group II (cPRs = 3 to 5) acylaminopenicillin/blI or cephalosporin 3b/4 or quinolone 2/3 or carbapenem 1
Group III (cPRs = 6 and more) cephalosporin 3b/4 or acylaminopenicilline/blI or carbapenem 1
Always in combination with either 
quinolone 2/3 or aminoglycoside*
* If the rate of MRsa among the staphylococcus aureus infections in a given hospital is >30%, the PEG recommends the in-
clusion of linezolid or vancomycin in the IIat. according to Pletz et al., the ZEPHyR study showed that linezolid is superior to
vancomycin in proven MRsa-pneumonia [32].
Table  2. data  collected  for  patients  included  in  the  final
analysis set.
Demographic characteristics
age
sex
Study-relevant data
onset-date
cPRs score
treatment group according to PEG guidelines
adequate IIat according to guidelines (yes/no)
clinical improvement
Treatment-related data
Initial diagnosis
dRG and related cW
length of stay
duration of mechanical ventilation
discharge code (death = code 7)
Economic data
total costs
costs on normal wards
costs incurred on Icu
total drug costs
drug costs on Icu
drug costs on general ward
Table 3.Primary and secondary endpoints of statistical analysis.
Endpoint Primary Secondary
clinical improvement X
survival (no discharge code 7) X
length of stay in hospital X
total costs (in hospital) X
Icu costs X
duration of mechanical ventilation X
total medication costs X
Medication costs on Icu X
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not be validated via chart review. 45 cases had aspira-
tion during or shortly after admission, 41 cases had
been transferred from another hospital (i.e. IIat start-
ed there) and 36 cases had pneumonia onset earlier
than 48 hours after admission. therefore, these three
groups did not meet the definition of HaP, i.e. pneu-
monia occurring 48 h or later after hospital admission
[25].  33  patients  had  an  Icu  stay  of  more  than  20
days, 2 cases had cystic fibrosis as underlying chronic
illness which is not covered by the general recommen-
dations for HaP/vaP. finally 1 patient was excluded
since he was readmitted within less than 14 days and
both stays were consolidated due to dRG regulations.
the cost data therefore do not longer reflect the hos-
pital stay in which the pneumonia occurred. 
after this process, 221 patients were included in the
final analysis set. shapiro-Wilkes test of the subpopu-
lations showed normal distribution of values in both
subpopulations. t tests on showed no significant dif-
ferences.
figure  1  provides  an  overview  of  the  inclusion
proc    ess. 
age, distribution of sex and mean cW of the pa-
tients as well as primary diagnosis and the type of in-
tervention (surgical, interventional, medical only) were
used  to  determine  whether  the  two  subpopulations
(adequate  vs.  inadequate  IIat)  were  comparable  at
baseline.  shapiro-Wilkes  test  was  used  to  check  for
normal distribution of values in both subpopulations.
student t test was used to check for significance of
differences. table 4 shows the baseline patient charac-
teristics of the final analysis set. there were no statis-
tically significant differences in patient distribution be-
tween the two subpopulations.
We then tested for significant differences in the pri-
mary  endpoints  clinical  improvement  and  survival.
table 5 shows the results of the chi-square test for
differences in clinical improveﾬment. the proportion
of patients with improvement was significantly higher
in patients with adequate therapy according to guide-
lines. 
table 6 shows the results of the chi-square test for
differences in survival. 
the  association  to  clinical  improvement  and  sur-
vival of possible cofactors such as age, gender, pres-
ence of neurological, cardiologic disease or polytrau-
ma was tested by logistic regression.
the rates of clinical improvement were 64% for all
patients,  82%  (85/104)  in  the  Ga-group  and  47%
(48/103) in the nGa group, respectively (p<0.001).
the odds ratio of therapeutic success with Ga versus
nGa treatment was 5.821 (p<0.001, [95% cI: 2.712-
12.497]). the odds ratio for age (elderly vs. non-elder-
ly) was 0.983 (p = 0.215, [95% cI: 0.957-1.010]), the
oR for gender (female vs. male) was 1.030 (p = 0.940
[95%  cI:  0.475-2.232])  and  the  oR  for  the  disease
groups (present vs. not present) was 1.048 (p = 0.902,
[95% cI: 0.496- 2.214]).
the survival rates were 80% for all patients, 86% in
the Ga-group (92/107) and 74% in the nGa-group,
respectively (0 = 0.021). the odds ratio of mortality
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Fig. 1. Patient distribution.
4. Wilke_Umbruchvorlage  12.07.11  11:32  Seite 318for  Ga  vs.  nGa  treatment  was  0.565  (p  =  0.117,
[95%  cI:  0.276-1.155]).  Having  neurological  disease,
cardiologic disease or polytrauma was found to be a
strong negative predictor of survival with an oR of
0.241 (p = 0.012, [95% cI: 0.096-0.609]). the odds ra-
tios for age (elderly vs. non-elderly) and gender (fe-
male vs. male) were 1.026 (p = 0.79, [95% cI: 0.997-
1.056]) and 1.246 (p = 0.545, [95% cI: 0.612-2.536]),
respectively.
for  the  subsequent  economical  analyses  the  pa-
tients with lethal outcome were excluded. all outcome
measures were compared via student t test.
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Table 4. baseline characteristics of the two subpopulations in the final analysis set.
Adequate IIAT according to PEG guidelines
Characteristics yes No p value
number of cases 107 114
Male / female 73 /34 73 /41
age (+/- sd) 63.4 (+/- 13.3) 65.2 (+/- 14.0) n.s.
dRG cost weight (+/- sd) 8.663 (+/- 5.947) 10.071 (+/- 5.882) n.s.
type of intervention
surgical procedure 102 99 n.s.
other procedure 54 n.s.
Medical 74 n.s.
Primary diagnosis (Icd 10 chapter)
I Infections and parasitic diseases 12 n.s.
II neoplasms 18 15 n.s.
III blood 32 n.s.
vI nervous system 44 n.s.
IX circulatory system 63 67 n.s.
X Respiratory system 22 n.s.
XI digestive system 42 n.s.
XIII Musculoskeletal system 21 n.s.
XIv Genitourinary system  10 n.s.
XvIII symptoms, signs and abnormal 
clinical and laboratory findings, 
not classified elsewhere 01 n.s.
XIX Injury, poisoning and other
consequences of external causes 16 11 n.s.
n.s. = not statistically significant
Table 5. clinical improvement according to Iaat adequacy. 
Adequate IIAT according to PEG guidelines
Yes No p value 
N =  104 103
Clinical improvement 85 48
(81.7%) (46.6%) < 0.001
* the table includes 207 patients. 14 patients of the final analysis set were excluded since clinical improvement was indetermi-
nate as follow-up x-ray images or laboratory results could not be retrieved.
Table 6. survival according to IIat adequacy.
Adequate IIAT according to PEG guidelines
Yes No p-value
N =  107 114
Survived 92 84
(85.6%) (73.7%) 0.021
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outcomes for the two subﾬpopulations (deceased pa-
tients excluded from analysis). 
Patients in the subpopulation with adequate IIat
show  a  significantly  shorter  length  of  stay  (23.9  vs.
28.3 days; p = 0.022), have significantly less hours of
mechanical  ventilation  (175  vs.  274;  p  =  0.001),  in-
curred lower total costs (EuR 28,033 vs. EuR 36,139;
p = 0.006) and lower Icu costs (EuR 13,308 vs. EuR
18,666, p = 0.003). drug costs for the hospital stay
were also lower (EuR 4,069 vs. EuR 4,833) yet not
significant.
We then analyzed the specific IIat used and ranked
the type of inadequacy of IIat. 
table 8 shows a comparison between chosen and
recommended PEG therapy groups. 
table 9 shows the frequencies of different types of
IIat inadequacy.
the most frequent type of inadequacy was mono  -
therapy in patients with a cPRs score of 6 or higher
(Group III) that should receive combination therapy
according  to  PEG  recommendations.  the  second
most  common  type  of  inadequacy  was  the  use  of
amino  penicillin/blI  (e.g.  amoxicillin/clavulanic  acid)
instead  of  an  acylaminopenicilin/blI  (e.g.  pipera  -
cilline/tazobactam) in cases having a cPRs score of
3-5 (Group II). another common deviation from the
PEG recommendation was the use of a cephalosporin
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Table 7. Economic outcomes according to IIat adequacy (deceased patients excluded from analysis).costs in €.
Adequate IIAT according to PEG guidelines
Means (+/- sd) Yes No Difference p value
N =  92 84 -- --
length of stay, days 23.9 28.3
(+/-12.9) (+/- 12.7) -4.5 0.022
duration of mechanical ventilation, hours 175 274
(+/- 174) (+/- 223) -99 0.001
Hospital costs
total costs, € 28,033 36,139
(+/- 16,574) (+/- 20,036) -8,106 0.006
total costs ward 3,062 2,918
(+/- 3,207) (+/- 3,216) 145 n.s.
total costs Icu 13,308 18,666
(+/- 10,706) (+/- 12,068) -5,358 0.003
Drug costs ᾬ
total drug costs 4,096 4,833
(+/- 4,061) (+/- 5,585) -737 n.s.
drug costs ward 655 622
(+/- 1,632) (+/- 1,783) 33 n.s.
drug costs Icu 2,083 2,372
(+/- 2,395) (+/- 2,412) -288 n.s.
Table 8. comparison of chosen vs. recommended PEG treatment group in the subpopulation with inadequate IIat (n = 114).
Recommended PEG treatment group according to CPRS score
Chosen therapy group I II III
therapy does not fit in any group 247
therapy group I  34 14
therapy group II 53
Total 2 38 74
Table 9. types of IIat inadequacy.
Type of deviation from PEG recommendation n =
Monotherapy instead of combination therapy 64
aminopenicillin/blI instead of  16
acylaminopenicillin/blI  16 
cephalosporin 3a instead of cephalosporin 3b/4
Wrong combination therapy 10
Wrong monotherapy (chosen antibiotic not in  4
recommendations)
no therapy at onset date of HaP/vaP 3
oral instead of intravenous medication 1
Total 114
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(e.g. ceftazidime) in cases having a cPRs score of 3-5
(Group II).
dIscussIon
the results of this study clearly show the clinical and
economical  superiority  of  adequate  initial  antibiotic
treatment according to PEG guidelines. although this
study is unique in combining analyses of clinical and
economical  outcomes  in  HaP/vaP  according  to
IIat  adequacy,  other  studies  reveal  similar  results.
orrick et al. performed an analysis with a very similar
design  for  community-acquired  pneumonia  (caP). 
In  their  dataset,  the  majority  of  patients  (75.8%) 
received preferred antibiotics according to the Idsa
guidelines.  the  group  treated  with  preferred  antibi-
otics  had  a  shorter  mean  length  of  hospital  stay 
(4.5 vs 6.8 days, p = 0.002), a lower total cost of hos-
pitalization (median usd 2,047 vs. 3,805, p = 0.021)
and lower antibacterial costs (median usd 97 vs. 171,
p = 0.038) compared with patients who did not re-
ceive the preferred therapy [33]. they concluded that
introducing  and  intensifying  adherence  to  Idsa
guidelines  reduces  the  economic  burden  associated
with caP.
bird  et  al.  performed  an  analysis  comparing  data
before vs. after introduction of a guideline for a vaP
prevention bundle in surgical Icus (sIcu). Prior to
the introduction of the bundle, vaP was recorded at a
rate of 10.2 cases per 1000 ventilator days. compli-
ance with the vaP bundle increased over the study pe-
riod from 53% and 63% to 91% and 81% in the par-
ticipating  sIcus,  respectively.  the  rate  of  vaP  de-
creased to 3.4 cases per 1000 ventilator days. Estimat-
ed cost savings amounted to usd 1.08 million [34].
the authors concluded that the initiation and intro-
duction of the bundle reduced the incidence of vaP
and associated cost.
Improved survival was also shown in a retrospective
analysis of caP cases by frei et al. they found that
guideline-discordant  therapy  was  associated  with  an
increase in inpatient mortality (25% vs. 11%; odds ra-
tio = 2.99 [95% cI, 1.08-9.54])[35].
ott et al. (2) investigated patients with HaP/vaP
and MRsa vs. Mssa as the underlying pathogen. for
MRsa patients, the cost differences were much higher
than in prior studies (€ 60,684 vs. € 38,731; p = 0.01).
Moreover, more patients died in the MRsa-group. (13
vs. 1 deaths, p < 0.001). We could not do a subgroup
analysis for the MRsa patients as we did not collect
microbiology results in our study.
In our study, the most frequent type of inadequate
IIat  was  monotherapy  when  the  guideline  recom-
mends a combination therapy. Particularly in patients
at high risk of involvement of complicated pathogens
(cPRs score of ≥6), the outcomes were significantly
better when an adequate IIat was chosen. this cor-
relation was well established in analyses performed by
Kollef et al., Kolenti et al. and other groups [8, 36-
38].
Possible limitations of our study include the follow-
ing. While the clinical and economical resource con-
sumption was not significantly different between the
subpopulation with adequate vs. inadequate IIat and
the  overall  morbidity  was  very  well  comparable,  we
found  a  significant  difference  in  the  cPRs  score
groups (3.5 +/-2.2 vs. 6.0 +/- 2.5). It appears that pa-
tients at higher risk of complicated pathogen involve-
ment are more likely to receive inadequate IIat. an-
other possible explanation is that experience-based lo-
cal standards for IIat are well sufficient for patients
with  lower  cPRs  score  but  inadequate  for  patients
with higher cPRs score. 
If  a  standard  therapy  regimen  is  applied  to  all
HaP/vaP  patients  without  applying  the  risk  score,
the number of adequately treated patients would be
lower in patients with high cPRs. this is underlined
by an analysis of IIat adequacy according to the PEG
therapy groups: more group I patients received ade-
quate IIat compared to group III patients who were
more likely to receive inadequate IIat.
However other cost drivers could have influenced
the differences between the subpopulations with ade-
quate vs. inadequate IIat. therefore we analysed cost-
relevant cPRs parameters with a significant difference
of occurrence in the Ga vs. nGa groups, the most
prominent being ‘extrapulmonary organ failure’ (1 vs.
12 patients) and ‘late onset’ (7 vs. 19 patients). logistic
regression did not reveal any significant associations
with cost, los or HMv. 
conclusIon
adequate  initial  intravenous  antibiotic  therapy  of
HaP/vaP according to PEG guidelines was clinically
superior and cost-saving vs. inadequate IIat. Rates of
survival rates and clinical improvement were signifi-
cantly higher in patients treated according to guideline
recommendations.  length  of  stay,  duration  of  me-
chanical  ventilation,  total  costs  and  Icu  costs  were
significantly  lower  as  well  for  the  subpopulation  re-
ceiving adequate IIat.
the  most  frequent  type  of  inadequate  IIat  was
monotherapy  in  patients  where  the  PEG  guidelines
recommend a combination therapy.
Moreover  it  appears  that  experience-based  thera-
peutic strategies which are most likely in place in every
hospital are mostly sufficient for patients with lower
risk for complicated pathogens but not for those with
a higher cPRs score. Educating physicians on guide-
line  recommendations  in  patients  with  higher  cPRs
scores – ideally adapted to the individual hospital’s re-
sistance patterns – may improve treatment adequacy
and  thus  outcomes  in  HaP/vaP  with  the  add-on
benefit  of  cost  reductions.  In  particular,  the  use  of
combination therapies as recommended by the guide-
lines may help to achieve a higher rate of adequate
IIat  and  thus  improve  clinical  outcomes  and  eco-
nomic parameters.
using the data from the German KIss surveillance
program [5] one could extrapolate an yearly number of
30,090 HaP/vaP cases in German Icus. assuming
that the observed rate of adequate IIat of less than
50%  was  generalizable  to  all  German  Icus  treating
HaP/vaP  patients,  the  consistent  use  of  IIat  ac-
cording to PEG guidelines may save 2,042 lives and
total costs of € 125,819,000. 
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